Selecting a reliable VIP supplier requires rigorous verification of peptide purity, analytical testing standards, and domestic manufacturing compliance. Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide widely studied in preclinical research for its receptor-mediated signaling pathways. This guide outlines the critical criteria laboratory procurement teams must evaluate when sourcing research-grade VIP for in vitro and animal models.
Selecting a reliable VIP supplier requires rigorous verification of peptide purity, analytical testing standards, and domestic manufacturing compliance. Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide widely studied in preclinical research for its receptor-mediated signaling pathways. This guide outlines the critical criteria laboratory procurement teams must evaluate when sourcing research-grade VIP for in vitro and animal models.
Vasoactive Intestinal Peptide (VIP) is a basic 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. Originally isolated from porcine duodenum, VIP functions as a non-adrenergic, non-cholinergic neurotransmitter and neuromodulator across various organ systems in preclinical models. Research interest in VIP focuses on its binding affinity for two distinct class B G-protein coupled receptors: VPAC1 and VPAC2. Preclinical studies suggest that VIP plays an integral role in regulating smooth muscle relaxation, secretomotor function, metabolic homeostasis, and immune cell signaling cascades.
When sourcing VIP for laboratory research, primary investigators must ensure the peptide maintains exact sequence fidelity (H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2). Because sequence truncations or oxidation at the methionine residue (position 17) can significantly attenuate receptor binding affinity in vitro, procurement specialists must partner with a specialized research peptide supplier capable of delivering high-purity, un-degraded material.
Selecting a reliable vendor requires a structured evaluation framework to prevent experimental batch variability and baseline contamination. When assessing a potential VIP supplier, laboratory procurement personnel should evaluate five fundamental operational and analytical domains: domestic synthesis capabilities, third-party verification, endotoxin quantification, cold-chain handling, and clear vendor risk-mitigation policies.
An initial checklist for laboratory auditing includes verifying domestic US synthesis under GMP-compliant manufacturing protocols, lot-specific Certificates of Analysis (COAs) generated by an independent ISO 17025 accredited laboratory, quantified endotoxin testing using standard Limulus Amebocyte Lysate (LAL) assays, robust cold-chain shipping protocols, and transparent replacement policies for non-conforming lots.
The geographical origin of peptide synthesis directly impacts conformational purity, trifluoroacetic acid (TFA) counter-ion removal, and overall lot-to-lot consistency. Overseas vendors frequently utilize high-throughput, low-cost liquid-phase synthesis techniques that result in accumulation of deleted peptides, racemized amino acids, and residual organic solvents. In contrast, domestic synthesis in USA-based, GMP-compliant facilities utilizes automated solid-phase peptide synthesis (SPPS) with rigorous in-line quality controls.
For sensitive cell culture assays or preclinical animal models, utilizing USA-synthesized VIP eliminates variables associated with uncontrolled transit conditions and regulatory customs delays. PX1 Research synthesizes and processes its peptides domestically, maintaining strict adherence to manufacturing guidelines. Sourcing from a domestic supplier provides verifiable supply chain transparency and ensures that every batch meets the exact chemical standards required for advanced preclinical investigation.
A core requirement when selecting a VIP vendor is access to transparent, lot-specific analytical documentation. General or 'representative' Certificates of Analysis are insufficient for scientific rigor. Laboratories must demand testing documentation executed on the specific lot being purchased. Two primary analytical methodologies must appear on every COA: High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS).
HPLC analysis provides a quantitative assessment of peptide purity, displaying the primary chromatographic peak relative to synthetic impurities, deletion sequences, and truncated fragments. For research-grade VIP, an HPLC purity threshold of ≥98% is strongly recommended to ensure reproducible binding assays. Mass Spectrometry (typically ESI-MS or MALDI-TOF) verifies the exact molecular weight of the peptide (monoisotopic mass ~3325.8 Da for VIP), confirming sequence integrity and the absence of heavy metal adduction or unexpected chemical modifications. PX1 Research provides batch-specific HPLC and MS reports generated by independent laboratories for total analytical transparency.
Bacterial endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—are common contaminants in synthetic peptide production. In cell culture models and rodent research, minute quantities of endotoxins can activate Toll-like receptor 4 (TLR4), triggering pro-inflammatory cytokine cascades that obscure cellular mechanisms and skew experimental outcomes.
When evaluating a VIP supplier, verification of low endotoxin levels is essential. Laboratories conducting sensitive biological assays should mandate peptides tested via chromogenic LAL assays with documented endotoxin levels below 0.1 EU/mg. Standardizing on endotoxin-tested research peptides prevents artifactual immune activation, ensuring that observed cellular responses are attributable solely to VIP VPAC1/VPAC2 receptor interaction rather than contaminant-driven pathways.
Vasoactive Intestinal Peptide contains oxidation-sensitive residues, specifically Methionine at position 17 and Tryptophan/Tyrosine sequences susceptible to photo-oxidation and thermal degradation. Proper formulation, packaging, and logistics are critical to maintaining structural stability from synthesis to reconstitution.
Suppliers must deliver VIP in a lyophilized (freeze-dried) cake format packed in argon-sparged, light-protected borosilicate glass vials. Lyophilization removes residual moisture, significantly retarding hydrolytic degradation. Additionally, efficient cold-chain handling ensures peptide stability during transit. PX1 Research operates distribution hubs in California and Arizona, providing same-day shipping from Monday through Friday. This dual-coast infrastructure minimizes transit times and thermal stress on sensitive compounds prior to arrival at your facility.
VIP belongs to a closely related family of neuropeptides that share homologous amino acid sequences and overlapping receptor affinities. When designing comparative binding or signaling assays, researchers frequently cross-evaluate VIP with other members of the secretin/glucagon peptide superfamily.
To establish robust experimental controls, procurement teams often source multiple peptides in this class simultaneously: PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide, which shares high sequence homology with VIP and binds VPAC1, VPAC2, and the selective PAC1 receptor), Secretin (the founding member of the superfamily, primarily activating the secretin receptor while demonstrating low-affinity cross-reactivity with VPAC receptors), and PHM-27 (Peptide Histidine Methionine, co-synthesized from the same prepro-VIP precursor gene). Evaluating these related compounds alongside VIP provides researchers with a comprehensive toolset for dissecting specific receptor-mediated pathways in vitro.
Procurement managers face significant operational risk if a supplier delivers sub-spec material or fails to maintain consistent inventory levels for longitudinal studies. When establishing a vendor relationship, evaluate their contractual quality guarantees and replacement policies.
A reputable vendor should maintain a clear refund or replacement protocol for any lot that fails independent laboratory re-verification. Furthermore, research teams requiring ongoing supply for multi-phase rodent trials or high-throughput screening assays should seek vendors offering dedicated wholesale lab accounts. PX1 Research offers structured bulk fulfillment options, batch reservation, and full quality guarantees, ensuring lab operations remain uninterrupted by material shortages or quality discrepancies.
Once high-purity VIP is delivered, proper handling in the laboratory is paramount to preserve bioactivity. VIP is supplied as a sterile lyophilized powder and should be stored at -20°C or -80°C upon arrival.
When preparing stock solutions for in vitro or animal models, researchers must follow strict aseptic techniques: reconstitute using sterile, preservative-free water or phosphate-buffered saline (PBS) depending on assay requirements (consult our peptide reconstitution guide for specific solubility parameters), avoid aggressive vortexing to prevent shear stress, and prepare single-use aliquots to eliminate freeze-thaw cycles that induce peptide aggregation.
Before submitting a purchase order for VIP, complete a final verification check of the vendor's analytical credentials and supply chain integrity. Confirming these critical factors mitigates technical risk and ensures high reproducibility across experimental replicates.
Summary Procurement Checklist: 1. Analytical Verification: Lot-specific HPLC (≥98%) and MS spectra available prior to purchase. 2. Endotoxin Standard: Quantified levels (<0.1 EU/mg) via LAL assay. 3. Manufacturing Origin: USA synthesis in ISO 17025 / GMP-compliant facilities. 4. Logistics: Lyophilized, vacuum-sealed packaging with same-day dispatch from CA/AZ. 5. Risk Mitigation: Guaranteed refund/replacement policies and wholesale account continuity.
What is the standard HPLC purity threshold for research-grade VIP?
For rigorous in vitro and preclinical research, VIP should have an HPLC purity of ≥98%. Lower purity levels introduce truncated sequences and organic impurities that can interfere with receptor binding assays.
Why is endotoxin testing critical when choosing a VIP supplier?
Endotoxins (LPS) trigger non-specific inflammatory responses via TLR4 activation in cell cultures and animal models. Ensuring endotoxin levels are below 0.1 EU/mg prevents false positive cytokine data in preclinical assays.
Where are PX1 Research peptides synthesized and processed?
All PX1 Research compounds are synthesized domestically in the USA within state-of-the-art, GMP-compliant facilities and tested by third-party ISO 17025 accredited laboratories.
How should lyophilized VIP be stored upon receipt?
Lyophilized VIP should be stored in a freezer at -20°C or -80°C upon arrival, protected from light and moisture. Unopened lyophilized vials remain stable under freezer conditions for up to 24 months.
What analytical reports are included with VIP from PX1 Research?
Every lot of VIP includes a lot-specific Certificate of Analysis (COA) containing High-Performance Liquid Chromatography (HPLC) chromatograms, Mass Spectrometry (MS) mass spectra, and LAL endotoxin test results.
How does VIP compare to PACAP in receptor binding studies?
In preclinical receptor affinity assays, VIP binds to VPAC1 and VPAC2 receptors with equal high affinity, but displays low affinity for the PAC1 receptor. PACAP binds VPAC1, VPAC2, and PAC1 with high affinity.
What solvent is recommended for reconstituting VIP for lab use?
VIP is typically reconstituted in sterile water for injection or sterile PBS (pH 7.4). Gentle agitation should be used rather than vortexing to avoid denaturing the peptide secondary structure.
What is PX1 Research's policy if a lot fails independent laboratory validation?
PX1 Research provides a full replacement or refund guarantee if any supplied compound fails to meet the specified purity or sequence parameters confirmed by independent third-party testing.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.